13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
31 檔
37.2%
In Q4 2024, Commodore Capital LP's U.S. equity holdings reached a combined market value of $1.7B, distributed across 31 disclosed stock positions.
In Q4 2024, Commodore Capital LP adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 9 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, PCVX, NUVL) accounted for 37.2% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 11.94% | — | +15.65% | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 9.75% | — | +76.63% | |
| 3 | NUVL | Nuvalent Inc-a | Stock-Other | 9.30% | -4.20% | +72.51% | |
| 4 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 7.87% | -2.78% | EXIT | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.93% | +2.47% | +2.56% | |
| 6 | VERA | Vera Therapeutics Inc | Stock-Other | 6.07% | — | -20.86% | |
| 7 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 5.02% | -1.26% | EXIT | |
| 8 | ALKS | Alkermes plc | Stock-Healthcare | 4.85% | +0.77% | -20.69% | |
| 9 | NRIX | Nurix Therapeutics Inc | Stock-Other | 4.14% | -2.04% | EXIT | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 3.93% | +0.60% | -8.73% | |
| 11 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.39% | -1.10% | — | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.37% | — | -5.89% | |
| 13 | SRRK | Scholar Rock Holding CORP | Stock-Other | 3.01% | — | — | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.72% | — | +64.33% | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 2.69% | -0.21% | — | |
| 16 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.20% | — | -46.14% | |
| 17 | ORKA | Oruka Therapeutics Inc | Stock-Other | 2.02% | — | +3.65% | |
| 18 | CRDF | Cardiff Oncology Inc | Stock-Other | 1.71% | — | — | |
| 19 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.41% | +0.13% | — | |
| 20 | NGNE | Neurogene Inc | Stock-Other | 1.34% | — | +300.00% | |
| 21 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.32% | — | — | |
| 22 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.18% | — | — | |
| 23 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.96% | — | — | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 0.69% | — | — | |
| 25 | ✓ | Stock-Other | 0.56% | — | — | ||
| 26 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.38% | — | — | |
| 27 | CELC | Celcuity Inc | Stock-Other | 0.38% | — | -73.72% | |
| 28 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.34% | +0.04% | NEW | |
| 29 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.26% | +0.70% | — | |
| 30 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.18% | — | -82.53% | |
| 31 | NKTX | Nkarta Inc | Stock-Other | 0.06% | — | -92.45% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | +3.3% | +72.51% | Add |
| 2 | PCVX | Vaxcyte Inc | +3.2% | +76.63% | Add |
| 3 | SRRK | Scholar Rock Holding CORP | +3% | NEW | New buy |
| 4 | NRIX | Nurix Therapeutics Inc | +1.8% | +81.82% | Add |
| 5 | CRDF | Cardiff Oncology Inc | +1.7% | NEW | New buy |
| 6 | ✓ | Merus N V | +1.5% | +15.65% | Add |
| 7 | IKT | Inhibikase Therapeutics Inc | +1.4% | NEW | New buy |
| 8 | 260 | Centessa Pharmaceuticals-adr | +1.4% | +64.33% | Add |
| 9 | DRUG | Bright Minds Biosciences Inc | +1.3% | NEW | New buy |
| 10 | XENE | Xenon Pharmaceuticals Inc | +1.2% | +1.48% | Add |
| 11 | SLNOEUR | Soleno Therapeutics Inc | +1% | +21.03% | Add |
| 12 | NGNE | Neurogene Inc | +0.8% | +300.00% | Add |
| 13 | PHVS | Pharvaris N.V. | +0.5% | — | Unchanged |
| 14 | ELVN | Enliven Therapeutics Inc | +0.4% | +2.56% | Add |
| 15 | ✓ | +0.1% | — | Unchanged | |
| 16 | ✓ | Helix Acquisition CORP Ii | +0.1% | — | Unchanged |
| 17 | VTGN | Vistagen Therapeutics Inc | 0% | — | Unchanged |
| 18 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 19 | ORKA | Oruka Therapeutics Inc | -0.1% | +3.65% | Add |
| 20 | ORIC | Oric Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 21 | APGE | Apogee Therapeutics Inc | -0.1% | — | Unchanged |
| 22 | ALKS | Alkermes plc | -0.2% | -20.69% | Trim |
| 23 | ABVX | Abivax Sa-adr | -0.2% | — | Unchanged |
| 24 | SYRE | Spyre Therapeutics Inc | -0.3% | — | Unchanged |
| 25 | VRDN | Viridian Therapeutics Inc | -0.3% | -5.89% | Trim |
| 26 | CABA | Cabaletta Bio Inc | -0.3% | EXIT | Sold out |
| 27 | TIL | Instil Bio Inc | -0.6% | EXIT | Sold out |
| 28 | BRD1EUR | Mind Medicine Mindmed Inc | -0.6% | -46.14% | Trim |
| 29 | VERA | Vera Therapeutics Inc | -0.8% | -20.86% | Trim |
| 30 | ✓ | Third Harmonic Bio Inc | -1% | -82.53% | Trim |
| 31 | CELC | Celcuity Inc | -1% | -73.72% | Trim |
| 32 | SNDX | Syndax Pharmaceuticals Inc | -1.1% | EXIT | Sold out |
| 33 | COGT | Cogent Biosciences Inc | -1.2% | -8.73% | Trim |
| 34 | CCCC | C4 Therapeutics Inc | -1.2% | EXIT | Sold out |
| 35 | NKTX | Nkarta Inc | -1.3% | -92.45% | Trim |
| 36 | ARVN | Arvinas Inc | -1.9% | EXIT | Sold out |
| 37 | RYTM | Rhythm Pharmaceuticals Inc | -2.1% | EXIT | Sold out |
| 38 | KURA | Kura Oncology Inc | -2.2% | EXIT | Sold out |
| 39 | CATX | Perspective Therapeutics Inc | -2.8% | EXIT | Sold out |
| 40 | CLDX | Celldex Therapeutics Inc | -3.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 31 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
SRRK
市值: $41.1M
Top Position Liquidated / Trimmed
CLDX
前期市值: $55.0M
During Q4 2024, Commodore Capital LP's top holdings by market value included MERUS N V (11.9%)、PCVX (9.8%)、NUVL (9.3%). The largest single position, MERUS N V, represented 11.9% of total portfolio value.
In Q4 2024, Commodore Capital LP made 31 total portfolio adjustments, initiating 4 new buys, adding to 10 positions, trimming 8 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.